New product: Vitrakvi (larotrectinib) 25mg and 100mg hard capsules
Licensed as monotherapy for treatment of patients with solid tumours that display an NTRK gene fusion, and who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.
Source:
electronic Medicines compendium